Commercial Availablility

The Zephyr® Endobronchial Valve and Chartis® System are CE mark approved and are commercially available in many countries outside of the United States.

The StratX Lung Analysis Platform, a cloud-based quantitative computed tomography (CT) analysis service is actually offered in Europe and APAC (Asia-Pacific).

StratX is designed to work in combination with the Chartis system to identify responders and non-responders for the Zephyr valve. AeriSeal, a foam-based lung sealant that is expected to significantly expand the treatable patient population for the company’s therapies, is available in a limited release in selected centers in Europe.